The signature CpGs also exhibited increased inter-tumor heterogeneity among the VavP-Bcl2+Aicda lymphomas, compared to relatively stable methylation states within VavP-Bcl2 controls (median VavP-Bcl2+Aicda IQR = 19.2%; median VavP-Bcl2 IQR = 5.56%; Fig. 2d). This evidence concerns the gene BCL2 and lymphoma.